FGF23
FGF23 (fibroblast growth factor 23) is a secreted member of the fibroblast growth factor family that regulates phosphate homeostasis and vitamin-D metabolism. It acts on the kidney and parathyroid, and its gene is linked to inherited disorders of phosphate balance. Browse Assay Genie's current range of FGF23 research reagents below, or read on for the biology behind the target.
FGF23 is a regulator of phosphate homeostasis. It inhibits renal tubular phosphate transport by reducing levels of SLC34A1, and it regulates vitamin-D metabolism. It also acts directly on the parathyroid to decrease PTH secretion. In the presence of KL, FGF23 up-regulates EGR1 expression. In addition, it negatively regulates osteoblast differentiation and matrix mineralisation, linking phosphate control to bone biology.
The FGF23 gene encodes a member of the fibroblast growth factor family, which is characterised by broad mitogenic and cell survival activities and involvement in many biological processes. FGF23 belongs to the heparin-binding growth factors family and is classed by HGNC among receptor ligands. The protein is secreted. The full-length, functional FGF23 protein may be deactivated by cleavage into N-terminal and C-terminal chains. Mouse and rat both have an Fgf23 ortholog.
FGF23 is clinically relevant because of its cleavage site. Mutation of this site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in the FGF23 gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC). These conditions make FGF23 a central subject in studies of phosphate handling, mineral metabolism and bone.
FGF23 regulates phosphate homeostasis and transport in the kidney by reducing SLC34A1 levels, making it a key factor in renal phosphate handling.
FGF23 regulates vitamin-D metabolism and acts directly on the parathyroid to decrease PTH secretion, connecting several endocrine axes.
FGF23 negatively regulates osteoblast differentiation and matrix mineralisation, so it is studied in bone formation and mineral metabolism.
Mutations in FGF23 are linked to autosomal dominant hypophosphatemic rickets and hyperphosphatemic familial tumoral calcinosis.
FGF23 is a secreted regulator of phosphate homeostasis. It inhibits renal tubular phosphate transport by reducing SLC34A1 levels, regulates vitamin-D metabolism, decreases PTH secretion by acting on the parathyroid, and negatively regulates osteoblast differentiation and matrix mineralisation. It up-regulates EGR1 expression in the presence of KL.
The full-length, functional FGF23 protein may be deactivated by cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Researchers may therefore distinguish full-length protein from cleaved fragments; check the datasheet of any product for its validated reactivity.
Mouse and rat each have an ortholog named Fgf23. In humans, FGF23 mutations are associated with autosomal dominant hypophosphatemic rickets and hyperphosphatemic familial tumoral calcinosis (HFTC). Check the datasheet of any product for its validated reactivity before use in a given species.
Other fibroblast growth factors, FGF-binding proteins and FGF receptors with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9GZV9; product specifications from Assay Genie datasheets.